The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

By Steve Cummings, S. Eckert, K. Krueger, D. Grady, T. Powles, J. Cauley, Larry Norton, T. Nickelsen, N. Bjarnason, M. Morrow and 5 more. 2000

700 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. (2002, background): “For estrogens, however, the observed association between their levels and breast cancer risk is probably causal for two reasons: 1) estrogens stimulate cell division (19) and 2) anti-estrogenic agents, such as tamoxifen, have been shown to be an effective treatment for early breast cancer (20), to r”
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006, result): “Previous studies have shown that raloxifenedoesnot increase the riskofuterinemalignancywhencomparedwithplacebo.(14,17,20) In the STAR trial, only 59 invasive uterine cancers were diagnosed in both study groups during more than 76 000 woman-years of follow-up.”
Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010, unknown): “Another SERM, raloxifene, has been shown to reduce the incidence of breast cancer in a series of clinical trials designed primarily to evaluate it for treatment and prevention of osteoporosis in postmenopausal women (7, 8).”